News written by Pankaj Singh


Precision For Medicine buys ApoCell to expand biomarker capabilities

Precision for Medicine has announced the acquisition of ApoCell, a Houston-based next-generation lab that specializes in the identification and analysis of biomarkers. By acquiring ApoCell, its ApoStream® liquid biopsy technology and extensive tissue profiling expertise will be added to Precision’s strong portfolio of specialty laboratory and biomarker informatics services. The …

Roche unveils NGS AVENIO Tumor Tissue Analysis Kits for research use

The Basel headquartered healthcare company Roche Holding AG has globally launched three next-generation sequencing AVENIO Tumor Tissue Analysis Kits for use in oncology research. The new AVENIO Tumor Tissue Targeted Kit, Surveillance Kit and Expanded Kit help to detect all four mutation classes in solid tumors and compliment Roche’s NGS …

Eli Lilly launches Olumiant in India, forays into autoimmune segment

The U.S. based pharmaceutical firm Eli Lilly and Company has reportedly announced to have forayed in the autoimmune segment in India. As per trusted sources, the drug maker has launched a new once-daily oral therapy, named as Olumiant, to treat rheumatoid arthritis. Reportedly, OlumiantTM is an advanced and effective once-daily …

BMS, Compugen announce $12M immunotherapy clinical trial partnership

Bristol-Myers Squibb (BMS) and Compugen, the Israeli genomics-based drug and diagnostic discovery company have made an announcement recently informing that the two companies have entered into a clinical trial partnership. The companies will undertake trial to evaluate COM701 from Compugen with Opdivo, BMS’s PD-1 immune checkpoint inhibitor, in patients having …

ImaginAb signs a multi-year licensing collaboration deal with Merck

ImaginAb, a California based immune and oncology imaging firm, has reportedly announced that it has signed a non-exclusive multi-year licensing collaboration with the New Jersey-based pharmaceutical company Merck & Company, Inc. As per the deal, Merck & Company, also known as Merck Sharp & Dohme (MSD) outside of Canada and …

ACell unveils research paper on hernia devices in regenerative drugs

The regenerative medicine firm Acell, Inc. has reportedly declared to published an article in the journal Regenerative Medicine titled ‘Comparison of in vivo remodeling of urinary bladder matrix and acellular dermal matrix in an ovine model’. As per trusted sources, the peer-reviewed publication compared the remodeling response and mechanical strength …

Lilly’s innovative 2-in-1 diabetes drug trials show impressive results

Pharmaceutical giant Eli Lilly and Co confirmed recently that the company’s new, two-in-one diabetes drug successfully lowered blood sugar and reduced weight in its trials. The announcement propelled Lilly’s shares to a record high whereas those of rival Novo Nordisk had dropped. Lilly’s innovative new drug is designed to target …

Health Canada bans valsartan from Chinese manufacturing unit

Health Canada, the government department responsible for national public health, in its recent announcement unveiled that it has found the manufacturing site of Chinese drug Zhejiang Huahai Pharmaceuticals to be non-compliant with the requirements of GMPs (Good Manufacturing Practices). GMPs, for the record, are international standards that help ensure that …